BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

...OASIS-1 trial in patients with moderate to severe plaque psoriasis. Data from the Phase III OASIS-2...
BioCentury | Mar 23, 2018
Financial News

After Ph II success, Arena raises $358.2M

...company said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
BioCentury | Mar 23, 2018
Clinical News

Arena's S1PR1 agonist meets in Phase II for UC

...NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
...Score (24.5% vs. 6%, p=0.004), which also includes Physician's Global Assessment (PGA) scores, vs. placebo. OASIS...
BioCentury | Mar 22, 2018
Financial News

Arena raises $352.8M after Phase II readout

...company said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
BioCentury | Mar 19, 2018
Clinical News

Arena's S1PR1 agonist meets in Phase II for UC

...NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
...Score (24.5% vs. 6%, p=0.004), which also includes Physician's Global Assessment (PGA) scores, vs. placebo. OASIS...
BioCentury | Jul 21, 2017
Clinical News

Paratek planning regulatory submissions for omadacycline antibiotic

...and skin structure infections (ABSSSIs) in the modified intent-to-treat (mITT) population of the Phase III OASIS-2...
BioCentury | Jul 17, 2017
Clinical News

Paratek antibiotic heading for submission

...said omadacycline (formerly PTK 0796) met FDA and EMA-specified co-primary endpoints in the Phase III OASIS-2...
...community-acquired bacterial pneumonia (CABP). Omadacycline has also met the primary endpoints in the Phase III OASIS-1...
...and CABP, respectively (see BioCentury Extra, June 16, 2016 & April 3, 2017) . In OASIS-2's...
BioCentury | Apr 3, 2017
Clinical News

Paratek's omadacycline meets second Phase III endpoint

...disease. Last year, Paratek said omadacycline met FDA and EMA endpoints in the Phase III OASIS...
...infections (ABSSSIs). On Monday, Loh said there was one death in the omadacycline arm in OASIS...
BioCentury | Jun 22, 2016
Financial News

Paratek raises $55.3M in follow-on

...omadacycline (formerly PTK 0796 ) met FDA- and EMA-specified primary endpoints in the Phase III OASIS...
BioCentury | Jun 20, 2016
Clinical News

Omadacycline: Phase III data

...Top-line data from the modified intent-to-treat (mITT) population of the double-blind, international Phase III OASIS trial...
Items per page:
1 - 10 of 60
BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

...OASIS-1 trial in patients with moderate to severe plaque psoriasis. Data from the Phase III OASIS-2...
BioCentury | Mar 23, 2018
Financial News

After Ph II success, Arena raises $358.2M

...company said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
BioCentury | Mar 23, 2018
Clinical News

Arena's S1PR1 agonist meets in Phase II for UC

...NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
...Score (24.5% vs. 6%, p=0.004), which also includes Physician's Global Assessment (PGA) scores, vs. placebo. OASIS...
BioCentury | Mar 22, 2018
Financial News

Arena raises $352.8M after Phase II readout

...company said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
BioCentury | Mar 19, 2018
Clinical News

Arena's S1PR1 agonist meets in Phase II for UC

...NASDAQ:ARNA) said high-dose etrasimod (APD334) met the primary and secondary endpoints in the Phase II OASIS...
...Score (24.5% vs. 6%, p=0.004), which also includes Physician's Global Assessment (PGA) scores, vs. placebo. OASIS...
BioCentury | Jul 21, 2017
Clinical News

Paratek planning regulatory submissions for omadacycline antibiotic

...and skin structure infections (ABSSSIs) in the modified intent-to-treat (mITT) population of the Phase III OASIS-2...
BioCentury | Jul 17, 2017
Clinical News

Paratek antibiotic heading for submission

...said omadacycline (formerly PTK 0796) met FDA and EMA-specified co-primary endpoints in the Phase III OASIS-2...
...community-acquired bacterial pneumonia (CABP). Omadacycline has also met the primary endpoints in the Phase III OASIS-1...
...and CABP, respectively (see BioCentury Extra, June 16, 2016 & April 3, 2017) . In OASIS-2's...
BioCentury | Apr 3, 2017
Clinical News

Paratek's omadacycline meets second Phase III endpoint

...disease. Last year, Paratek said omadacycline met FDA and EMA endpoints in the Phase III OASIS...
...infections (ABSSSIs). On Monday, Loh said there was one death in the omadacycline arm in OASIS...
BioCentury | Jun 22, 2016
Financial News

Paratek raises $55.3M in follow-on

...omadacycline (formerly PTK 0796 ) met FDA- and EMA-specified primary endpoints in the Phase III OASIS...
BioCentury | Jun 20, 2016
Clinical News

Omadacycline: Phase III data

...Top-line data from the modified intent-to-treat (mITT) population of the double-blind, international Phase III OASIS trial...
Items per page:
1 - 10 of 60